SHERP

Efficacy of paclitaxel and carboplatin as a regimen for postoperative concurrent chemoradiotherapy of high risk uterine cervix cancer

Cited 0 time in webofscience Cited 0 time in scopus
Authors
Kim, Kyubo; Chie, Eui Kyu; Wu, Hong-Gyun; Ha, Sung W; Kim, Jae Sung; Kim, In Ah; Lee, Hyo-Pyo
Issue Date
2005-11-07
Publisher
Elsevier
Citation
Gynecol Oncol. 2006 Jun;101(3):398-402. Epub 2005 Dec 5.
Keywords
AdultAgedAntineoplastic Combined Chemotherapy Protocols/adverseeffects/*therapeutic useCarboplatin/administration & dosage/adverse effectsCombined Modality TherapyDisease-Free SurvivalFemaleHumansHysterectomyLymph Node ExcisionMiddle AgedNeoplasm StagingPaclitaxel/administration & dosage/adverse effectsPatient ComplianceRadiotherapyRisk FactorsUterine Cervical Neoplasms/drug therapy/pathology/radiotherapy/*therapy
Abstract
OBJECTIVE: To evaluate the efficacy and safety of concurrent chemoradiotherapy with paclitaxel and carboplatin after hysterectomy for early stage uterine cervical carcinoma with high risk factors. METHODS: Between March 2000 and July 2002, 37 patients with stages IB-IIB uterine cervical carcinoma were treated with radical hysterectomy and bilateral pelvic lymph node dissection followed by concurrent chemoradiotherapy (POCCRT) with two courses of paclitaxel (135 mg/m(2)) and carboplatin (area under the time-concentration curve 4.5 mg min/ml) at 4-week interval. All the patients received external beam radiotherapy up to 50.4 Gy to the whole pelvis. Among these, 7 patients with close or involved resection margin received boost irradiation to the vaginal cuff (4 patients with low dose rate brachytherapy and 3 patients with external beam). Median dose of boost irradiation was 14.4 Gy (range: 14.4-34.6). RESULTS: Toxicity to POCCRT was mainly hematological and gastrointestinal, mostly grades 1 and 2. At a median follow-up of 27 months (range; 10-46), all the patients achieved local control, and 4 patients experienced distant relapses. The failure sites were as follows: bone (2 patients), paraaortic lymph node (1 patient), and supraclavicular lymph node (1 patient). CONCLUSIONS: Concurrent chemoradiotherapy with paclitaxel and carboplatin after hysterectomy is well tolerated and produces excellent local control rate despite of short follow-up period. This regimen could be considered for a phase III trial.
ISSN
0090-8258 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16330087

http://hdl.handle.net/10371/15514
DOI
https://doi.org/10.1016/j.ygyno.2005.10.035
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Obstetrics & Gynecology (산부인과전공)Journal Papers (저널논문_산부인과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse